Distribution and genotype-phenotype correlation of GDAP1 mutations in Spain by Sivera R et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a Creative Commons Attribution 4.0 International License 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Sivera R, Frasquet M, Lupo V, Garcia-Sobrino T, Blanco-Arias P, Pardo J, 
Fernandez-Torron R, De Munain AL, Marquez-Infante C, Villarreal L, Carbonell 
P, Rojas-Garcia R, Segovia S, Illa I, Frongia AL, Nascimento A, Ortez C, Garcia-
Romero MDM, Pascual SI, Pelayo-Negro AL, Berciano J, Guerrero A, 
Casasnovas C, Camacho A, Esteban J, Chumillas MJ, Barreiro M, DIaz C, Palau 
F, Vilchez JJ, Espinos C, Sevilla T. Distribution and genotype-phenotype 
correlation of GDAP1 mutations in Spain. Scientific Reports 2017, 7, 6677. 
 
Copyright: 
This article is licensed under a Creative Commons Attribution 4.0 International License, which 
permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as 
you give appropriate credit to the original author(s) and the source, provide a link to the Creative 
Commons license, and indicate if changes were made. The images or other third party material in 
this article are included in the article’s Creative Commons license, unless indicated otherwise in a 
credit line to the material. If material is not included in the article’s Creative Commons license and 
your intended use is not permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a copy of this license, visit 
http://creativecommons.org/licenses/by/4.0/. 
DOI link to article: 
10.1038/s41598-017-06894-6 
Date deposited:   
07/08/2017 
1SCIENTIFIC REPORTS | 7:  6677 | DOI:10.1038/s41598-017-06894-6
www.nature.com/scientificreports
Distribution and genotype-
phenotype correlation of GDAP1 
mutations in Spain
Rafael Sivera1, Marina Frasquet2,3, Vincenzo Lupo4, Tania García-Sobrino5, Patricia Blanco-
Arias6,7,8, Julio Pardo5, Roberto Fernández-Torrón9,10,11,12, Adolfo López de Munain9,11,12,13, 
Celedonio Márquez-Infante14, Liliana Villarreal14, Pilar Carbonell14, Ricard Rojas-García8,15, 
Sonia Segovia8, Isabel Illa8,15, Anna Lia Frongia16, Andrés Nascimento8,16, Carlos Ortez8,16, 
María del Mar García-Romero17, Samuel Ignacio Pascual17,18, Ana Lara Pelayo-Negro12,19,20, 
José Berciano12,19,20, Antonio Guerrero21, Carlos Casasnovas22, Ana Camacho23,24, Jesús 
Esteban25,26, María José Chumillas27, Marisa Barreiro3, Carmen Díaz28, Francesc Palau8,29,30,31, 
Juan Jesús Vílchez  2,3,8,32, Carmen Espinós4 & Teresa Sevilla  2,3,8,32
Mutations in the GDAP1 gene can cause Charcot-Marie-Tooth disease. These mutations are quite rare 
in most Western countries but not so in certain regions of Spain or other Mediterranean countries. 
This cross-sectional retrospective multicenter study analyzed the clinical and genetic characteristics 
of patients with GDAP1 mutations across Spain. 99 patients were identified, which were distributed 
across most of Spain, but especially in the Northwest and Mediterranean regions. The most common 
genotypes were p.R120W (in 81% of patients with autosomal dominant inheritance) and p.Q163X (in 
73% of autosomal recessive patients). Patients with recessively inherited mutations had a more severe 
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phenotype, and certain clinical features, like dysphonia or respiratory dysfunction, were exclusively 
detected in this group. Dominantly inherited mutations had prominent clinical variability regarding 
severity, including 29% of patients who were asymptomatic. There were minor clinical differences 
between patients harboring specific mutations but not when grouped according to localization or 
type of mutation. This is the largest clinical series to date of patients with GDAP1 mutations, and it 
contributes to define the genetic distribution and genotype-phenotype correlation in this rare form of 
CMT.
Mutations in the ganglioside-induced differentiation-associated protein 1 (GDAP1) gene cause different forms 
of Charcot–Marie–Tooth disease (CMT). Autosomal recessive mutations have been described in patients with 
axonal, intermediate and demyelinating forms of the disease, while dominantly inherited mutations cause axonal 
CMT1–4. These mutations are quite rare in Western countries, accounting for less than 1% of the genetically 
defined CMT patients in most clinical series5, 6. In contrast, in certain regions of Spain and Italy, these mutations 
are the most frequent cause of axonal CMT, accounting for up to 10% of the genetic diagnosis in CMT7–9.
The GDAP1 gene encodes a protein belonging to a glutathione S-transferase (GST) enzyme subfamily in chro-
mosome 8q21.110. GDAP1 is localized in the outer mitochondrial membrane, and is composed of two typical GST 
domains at the N and C-terminal regions, two alpha loops, a single transmembrane domain, and a hydrophobic 
domain. Although no GST activity has been demonstrated so far, GDAP1 is involved in the regulation of mito-
chondrial dynamics and calcium homeostasis11, 12.
GDAP1 autosomal recessive (AR) inherited mutations cause a severe, early onset neuropathy often leading to 
wheelchair-dependency in the second or third decade. Most of these patients develop unilateral or bilateral vocal 
cord paresis, and diaphragmatic weakness in the latter stages of the disease13. It has been suggested that recessive 
mutations which cause truncating proteins develop a more severe phenotype, while missense mutations may be 
associated with a slightly milder course14.
On the other hand, autosomal dominant (AD) inherited mutations cause a much milder phenotype, charac-
terized by adult onset, predominantly distal involvement, and slow progression, most of these patients remaining 
ambulant throughout their lives15, 16. Certain clinical characteristics, like dysphonia or dysautonomia, have been 
described in isolated patients, but no clear genotype-phenotype correlation has been established in AD inherited 
mutations9, 17.
The aim of the study is to describe the distribution of patients with GDAP1 mutations across Spain and to 
expand the knowledge of the clinical course and the genotype-phenotype correlation.
Results
We identified 99 patients from 46 different families harboring causative GDAP1 mutations. There was no sex pre-
dominance in the series and ages ranged from 3–79 years. There were three patients in which only genetic infor-
mation was available. Nerve conduction studies were performed in 75 patients while other ancillary tests were 
less frequently performed: leg muscle magnetic resonance imaging in 22 cases and sural nerve pathology in 15.
Genotype. The genetic information is recorded in Table 1. Thirteen different mutations were detected, 3 
inherited in an autosomal dominant fashion and the other 10 were recessive. All had been previously reported. 
The two most common mutations were AD p.R120W, and AR p.Q163X. The type of mutations was quite diverse 
including 6 missense, 4 nonsense, 2 frameshift mutations and one splice-site variant. They were localized along 
exons 2–6 and affected the 2 GST domains and the α-loop predominantly. A schematic diagram of the GDAP1 
protein and the mutations found in this series is reproduced in Fig. 1.
The AD p.R120W was detected predominantly in families near the Mediterranean coast, while p.R226del 
was found only in two families in the region of Galicia, in the Northwest of Spain (Fig. 2). The AR patients were 
distributed throughout Spain, but there existed a cluster of affected individuals in the North of Spain, especially 
in the Basque country and neighboring regions.
Clinical characteristics. The clinical features of the series are summarized in Table 2. Patients were sepa-
rated between AD and AR inherited mutations because all the severity scores and certain clinical features were 
different between the groups.
Patients with AD inherited mutations had a mild-moderate neuropathy with variable age of onset (4–65 
years). The first symptoms most commonly reported were distal lower leg weakness and cramps (83%). Foot 
deformities (pes cavus, Achilles tendon contracture or hammer toes) were quite common (85.2%), but only one 
patient presented scoliosis and none dysphonia or respiratory failure. Severity scores were usually between the 
mild-moderate range, and 28.6% considered themselves asymptomatic. There was important clinical variability 
regarding severity scores even between family members as can be seen in the pedigree of Fig. 3. Three patients 
died during follow-up, but the cause of death was not related with the neuropathy.
Patients with AR inherited mutations suffered a severe early onset neuropathy (0–12 years) causing a great 
disability. Most of the patients were wheelchair-bound before age 20, and only three patients older than 40 years 
remained ambulant. Dysphonia was present in more than half of the AR patients and appeared usually in the 
second decade (9–35 years). Respiratory dysfunction was also quite common, and 19.5% of the patients required 
non-invasive ventilation (29–47 years). Intra-familiar variability was not prominent, although most were sporadic 
patients. Six patients died, two because of cardiovascular events, one of hepatic cirrhosis, and three due to infec-
tions that could be related to the severe disability inherent to the disease course.
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Nerve conduction studies. The electrophysiological findings are detailed in Table 3. In AD patients there 
was a decrease of CMAP and SNAP amplitudes with normal conduction velocities, corresponding to a mild 
axonal motor and sensory neuropathy. Of the 12 clinically asymptomatic patients that underwent nerve con-
duction studies, in 8 we detected a decrease in SNAP of the sural nerve and/or CMAP of the peroneal nerve. The 
other 4 asymptomatic patients had normal nerve conduction studies, but 3 of them had detectable abnormalities 
in needle electromyography (large polyphasic motor unit action potentials in distal lower limb muscles with no 
spontaneous muscular activity), while it was not performed in the other patient.
In AR patients the decrease in CMAP and SNAP was much more marked, as were the number of nerves that 
were unexcitable when explored. These findings were more severe in the lower limb nerves; in fact all patients 
over 25 years had unexcitable sural and peroneal nerves. Conduction velocities were generally not reduced except 
in nerves with very low amplitudes (Fig. 4b). In these cases, when conduction velocity was measured to proximal 
muscles, it was always within the normal range.
Muscle magnetic resonance imaging. Lower limb muscle magnetic resonance imaging findings are 
detailed in Table 4, and representative images are shown in the supplementary Figure S1. It was performed in 22 
patients, 19 of them harboring the AD p.R120W mutation. In those patients the findings were in concordance 
with that previously reported including fatty infiltration with a distal to proximal gradient16. In 3/5 clinically 
asymptomatic patients, there was detectable fatty substitution in the intrinsic foot muscles and in 2/5 also in the 
Nucleotide Amino acid Effect Exon Domain Patients Families Region Reference
Dominantly inherited
c.358 C > T p.R120W Missense 3 GST-N 47 15 Widespread Claramunt R, et al. 4
c.677_679del p.R226del Deletion 5 GST-C 10 2 Galicia García-Sobrino T, et al. 30
c.469 A p.T157P Missense 3 α-loop 1 1 Asturias Claramunt R, et al.4
Recessively inherited
c.487 C > T/c.487 C > T p.Q163X/p.Q163X Nonsense 4 α-loop 22 15 North of Spain, Basque region Cuesta A, et al.
1
c.487 C > T/c.863insA p.Q163X/p.T288NfsX3 Nonsense/Frameshift STOP 4/6 α-loop 2 1 Valencia Cuesta A, et al. 
1
c.487 C > T/c.1031 T > G p.Q163X/p.L344R Nonsense/Missense 4/6 α-loop 1 1 Cadiz Sivera R, et al.
7
c.487 C > T/c.581 C > G p.Q163X/p.S194X Nonsense 4/5 α-loop 4 2 Valencia, Asturias Cuesta A, et al.
1
c.487 C > T/c.342_345del p.Q163X/p.E114fsX145 Nonsense 4/3 α-loop /GST-N 1 1 País Vasco
Claramunt R, 
et al.4
c.581 C > G /c.863insA p.S194X/p.T288NfsX3 Nonsense/Frameshift STOP 5/6 α-loop 2 2 Valencia
Claramunt R, 
et al.4
c.172_173delinsTTA/c.311-1 G > A p.P59AfsX4/splicing variant
Frameshift STOP/
No effect 2/int 2 GST-N 1 1 Alicante
Sevilla T, et al. 
200813
c.844 C > T/c.844 C > T p.R282C/p.R282C Missense 6 GST-C 2 1 León Nelis E, et al.31
c.863insA/c.863insA p.T288fsX3/p.T288fsX3 Frameshift STOP 6 α-loop 1 1 Valencia Cuesta A, et al. 20021
c.703 C > G/c.703 C > G p.Q235X/p.Q235X Nonsense 6 GST-C 1 1 Baleares Ortez C, et al. 32
c.458 C > T/c.458 C > T p.P153L/p.P153L Missense 3 α-loop 2 1 Ávila Kabzinska D, et al.33
c.233 C > T/c.233 C > T p.P78Lp.P78L Missense 2 GST-N 2 1 Madrid/Morocco
Bouhuche A, 
et al.34
Table 1. Genotype distribution and effects. GST-N: glutathione S-transferase domain in the N-terminal region, 
GST-C: glutathione S-transferase domain in the C-terminal region.
Figure 1. Localization in the GDAP1 gene of the mutations detected. AD: Autosomal dominant, AR: 
Autosomal recessive, in blue: missense mutations, in red: truncating mutations.
www.nature.com/scientificreports/
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muscles of the calf. In the 2 asymptomatic patients with normal muscle MRI, the muscles of the feet were not 
studied. In the calf, the muscles of the posterior compartment (soleus > gastrocnemius) were affected earlier and 
more severely than those of the anterolateral compartment.
MRI was performed in two patients with the AD p.R226del mutation. In one symptomatic patient there were 
detectable abnormalities consisting in fatty infiltration with a distal to proximal gradient, and the same pos-
terior > anterolateral pattern in the calf. The other was asymptomatic, although minor abnormalities could be 
detected in the clinical examination. The muscle MRI in this patient was normal in the calf and thigh muscles, 
but the feet were not studied.
Figure 2.  Patient distribution throughout Spain AD: Autosomal dominant, AR: Autosomal recessive, light blue 
diamond: patient with the AD p.R120W mutation, dark blue diamond: patient with the AD p.R226del mutation, 
medium blue diamond: patient with the AD p.T157P mutation, red square: patient with AR mutations. The 
map was created with SimpleMappr, an online tool to produce publication-quality point maps. [Retrieved from 
http://www.simplemappr.net. May 24, 2017]; Shorthouse, David P. 2010.
AD inheritance AR inheritance Total
n 58 41 99
families 18 28 46
Sex (M/F) 25/33 24/17 49/50
Age at 1rst visit 42.1 yrs (8–79) 27.2 yrs (3–54) 36.4 yrs
Follow up* 7 yrs 9.9 yrs 8.4 yrs
Age of independent walking* 12 months 15.2 months 13.3 months
Age of onset* (range) 23.8 yrs (4–65) 2.5 yrs (0–12) 13.4 yrs
Asymptomatic (%) 16 (28.6%) 0 (0%) 16 (16.7%)
Sensory symptoms 32 (57.1%) 30 (76.9%) 62 (65.3%)
Motor symptoms 36 (64.3%) 39 (100%) 75 (78.9%)
Autonomic symptoms 0 7 (18.4%) 7 (7.4%)
CMTNS* 7.3 (0–26) 22 (8–32) 13.6
CMTES* 4.6 (0–21) 15.8 (4–23) 8.9
FDS* 1.3 (0–6) 5.2 (2–7) 2.8
Wheelchair-bound (%) 0 30 (75%) 30 (30.9%)
Age wheelchair (yrs) NA 15,1 (7–52) 15,1 (7–52)
Distal deformities (%) 46 (85.2%) 35 (92.1%) 81 (88%)
Dysphonia (%) 0 22 (56.4%) 22 (23.7%)
Respiratory failure (%) 0 21 (52.5%) 21 (21.2%)
Scoliosis (%) 1 (1.9%) 22 (56.4%) 23 (23.7%)
Death (%) 3 (5.2%) 6 (14.6%) 9 (10%)
Age of death* (yrs) 72 (64–82) 55.7 (42–71) 61.1 (42–82)
Table 2. Clinical characteristics. *Mean values, AD: Autosomal dominant, AR: Autosomal recessive, yrs: years, 
CMTNS: Charcot-Marie-Tooth neuropathy score, CMTES: Charcot-Marie-Tooth examination score, FDS: 
functional Disability Scale, yrs: years, NA: Not applicable. For the % values only the patients with available 
information were included.
www.nature.com/scientificreports/
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One patient with an AR p.Q163X/p.L344R mutation also underwent muscle MRI testing. He was the AR 
patient with the less severe phenotype (CMT neuropathy score - CMTNS: 12, Functional disability score - FDS: 
2, age 49 at the time of the MRI) and there was complete fatty substitution of the muscles in the feet and posterior 
compartment of the calf, but in the anterolateral muscles of the calf and the thigh muscles, fatty infiltration was 
only partial.
Nerve pathology. Sural nerve biopsy was performed in 15 patients, 8 with AR and 7 with AD inherited 
mutations. Representative images are shown in the supplementary Figure S1. The pathologic characteristics of 
7 of these patients had been previously been reported, and are similar to the other 8 patients1, 16, 18. The main 
findings were concordant with an axonal neuropathy (depletion of myelinated fibers, myelin thinning, and rather 
frequent regenerative clusters) with minor myelin abnormalities (abnormal myelin foldings and occasional onion 
bulb-like formations). The fiber loss was especially prominent in AR patients.
Genotype-phenotype correlation. The most important genetic factor that influenced the phenotype was 
the mode of inheritance. Certain clinical features like the presence of dysphonia and respiratory dysfunction were 
only present in patients with AR inheritance and scoliosis was more frequent in patients with AR inheritance 
(p < 0.001) (Table 2). In this group, 75% of the patients were wheelchair-bound at a median age of 15 years. By 
contrast none in the group of AD inheritance lost ambulation with a median follow-up of nearly 7 years. The 
presence of any kind of neuropathic symptoms was more frequent in patients with AR inheritance, as were higher 
severity scores in any of the scales employed (p < 0.05). In Fig. 4a the CMTNS scores of the first examination in 
both groups can be compared. With a logistic regression model, the only co-variables that could independently 
predict a higher CMTNS score were the mode of inheritance: OR 38, CI 95% [4–474.2] and the disease duration 
OR 1.1 CI 95% [1.05, 1.19].
Regarding the patients with AD inheritance, we detected minor clinical differences between the two most 
frequent mutations. The members of the two families with the p.R226del mutation had a slightly milder disease 
course. Also, in the p.R120W mutation ankle extensors and flexors were affected to a similar degree (3.9 and 3.7 
mean MRC scores respectively) while in those with the p.R226del mutation weakness was more marked in ankle 
extension (4.3 and 4.7 mean MRC scores).
In the patients with AR inherited mutations no clinical differences could be detected when grouping patients 
according to localization of the mutation or mutation type. Neither could we detect any statistically significant dif-
ference in age of onset, years to wheelchair, or other severity scores between patients with ‘truncating’ mutations 
and those with two missense mutations. In patients with the same mutation, clinical variability regarding severity 
was not prominent. Regarding specific mutations, the only two patients with the homozygous p.R282C mutation 
seemed to have a milder clinical course, as did the only patient compound heterozygous for the p.Q163X and 
p.L344R mutations.
Discussion
This multicentric cross-sectional study provides information about 99 patients with CMT caused by GDAP1 
mutations. In Spain the relative frequency of GDAP1 mutations has been reported to be as high as 13% of the 
genetically defined CMT in certain regions7. Patients in this series were distributed throughout Spain, and in 
Figure 3. Clinical variability in a family harboring the AD p.R120W mutation. yrs: years, LL: Lower limbs, 
CMTNS: Charcot-Marie-Tooth neuropathy score, CMTES: Charcot-Marie-Tooth examination score.
www.nature.com/scientificreports/
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most centers comprised the first cause of CMT2, excluding GJB1 mutations. This contrasts with the scarcity of 
these mutations in most Western Countries, accounting for less than 2% of the genetically defined patients in 
series from the United Kingdom, Germany, United States, and also in the cohort of patients from the Inherited 
Neuropathies Consortium5, 6, 19, 20. On the other hand, there have been reports of regional Italian clinical CMT 
series that found frequencies of GDAP1 mutations of > 7%, and after analyzing a group of patients referred to the 
Medical Genetics Unit of the University of Genoa, the authors conclude that GDAP1 mutations should be the first 
genetic diagnosis to be considered in an Italian patient with CMT28, 9. Further information about the relative fre-
quency of GDAP1 mutations in the South of France and other countries of the Mediterranean coastline (Greece, 
Turkey, Morocco, etc.) will be needed to clarify the geographical distribution of these mutations.
AD inheritance AR inheritance Total
n 48 28 76
Age NCS* 38.5 yrs (8–82) 20.2 yrs (2–48) 30.8 yrs
Disease course 
NCS* 18 yrs 17.3 yrs 17.6 yrs
Ulnar CMAP* 10.7 mV (0.9–20.6) 3.8 mV (0.1–9.1) 9.5 mV
Ulnar MCV* 58.4 m/s (47.3–68) 43.9 m/s (42–57.6) 55.4 m/s
% Unexcitable 0/27 (0%) 12/19 (63.2%) 12/46 (26.1%)
Median CMAP* 9.7 mV (3.2–23.4) 2 mV (0.4–11.7) 7.6 mV
Median MCV* 56.6 m/s (48–69.1) 42 m/s (30.4–66.7) 53.4 m/s
% Unexcitable 0/39 (0%) 11/23 (47.8%) 11/64 (17.2%)
Peroneal CMAP* 4.8 mV (0.3–11.9) 0.5 mV (0.3–0.6) 4.5 mV
Peroneal MCV* 44.8 m/s (38–61) 40.1 m/s (40.1) 44.7 m/s
% Unexcitable 7/47 (14.9%) 18/20 (90%) 25/67 (37.3%)
Ulnar SNAP* 10.7 μV (1.4–27) 2.1 μV (0.2–6.1) 8.5 μV
Ulnar SCV* 48.4 m/s (34.7–64.7) 46.1 m/s (34.3–55.7) 47.8 m/s
% Unexcitable 2/22 (9.1%) 8/14 (57.1%) 10/36 (27.8%)
Median SNAP * 11.4 μV (1.6–32.6) 3.5 μV (0.2–16) 9.2 μV
Median MCV* 47.7 m/s (36.3–65.1) 40.8 m/s (30.4–53) 45.7 m/s
% Unexcitable 4/39 (10.3%) 14/26 (53.8%) 18/65 (27.7%)
Sural SNAP* 5.5 μV (0.7–13.9) 4,8 μV (2.6–7.2) 5.5 μV
Sural SCV* 43.1 m/s (29–65.9) 46.8 m /s (43.9–49.6) 43.4 m /s
% Unexcitable 18/46 (39.1%) 19/22 (86.4%) 37/68 (54.4%)
Table 3. Motor and sensory nerve conduction studies. *Mean values, AD: Autosomal dominant, AR: 
Autosomal recessive, NCS: Nerve conduction studies, CMAP: Compound muscle action potential, MCV: motor 
conduction velocity, SNAP: Sensory nerve action potential, SCV: sensory conduction velocity, yrs: years, mV: 
millivolts, μV: microvolts. For the % values only the patients with available information were included.
Figure 4. (a) Dispersion chart of the CMTNS scores and ages in the first examination of patients with AD and 
AR inherited mutations. (b) Dispersion chart of the CMAP of the median nerve the motor conduction velocity 
in patients with AD and AR inherited mutations. AD: Autosomal dominant, AR: Autosomal recessive, CMTNS: 
Charcot-Marie-Tooth neuropathy score, CMAP: Compound muscle action potential.
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In Spain, the high frequency of GDAP1 mutations among CMT2 patients is in part due to the high frequency 
of two mutations. The p.R120W substitution accounted for 81% of AD patients and was detected mostly in the 
Mediterranean basin, while p.Q163X was detected either as a homozygous or compound heterozygous mutation 
in 73.2% of AR patients, especially in the North/Northwest of Spain. Both of these mutations had been studied 
previously with haplotype analysis and postulated as having a founder effect in the region, although they have 
been detected in families in other European and American countries1, 16, 21.
Regarding the phenotype, the most important factor that influences the clinical characteristics of these 
patients is the mode of inheritance (Table 2). The patients with AR inherited mutations have a more severe course 
and certain clinical features like dysphonia and respiratory dysfunction were exclusively found in this group13, 18. 
In fact when the CMTNS scores of the series were modeled with a logistic regression analysis, the only factor that 
could independently predict higher CMTNS scores apart from disease evolution was AR inheritance. Although 
AR patients had a more severe course as a group, there existed a certain overlap between the severity scores when 
grouped by the inheritance pattern (Fig. 4a).
For example, there were two AR patients with a milder phenotype than the rest of the cohort (CMTNS scores 
of 12 and 16 at ages 49 and 46 respectively). The latter is still ambulant with crutches at 56 years of age, and 
harbors the homozygous missense p.R282C change. This mutation has only been detected in him and his sister, 
who has a slightly more severe phenotype and became wheelchair-bound only at age 52. The other patient was a 
compound heterozygous for p.Q163X and p.L344R, and remained ambulant with orthosis until his death due to 
hepatic cirrhosis at age 55. Even taking into account these outliers, when the clinical characteristics or severity 
scores were compared according to the localization of the mutation or mutation type, no differences could be 
established. It has been reported that patients with two ‘truncating’ mutations have a more severe phenotype than 
those with two missense mutations, but when we compared age of onset, years to wheelchair or other impairment 
scores we could not replicate these findings14.
In patients with AD inheritance, phenotypic variability regarding severity was prominent, even within affected 
members of the same family. There are three AD patients with a severe neuropathy according to CMTNS, one of 
them needing a walker for ambulation; while 28.6% considered themselves asymptomatic, two of them older than 
70 years. The factors that influence this variability are largely unknown, but the search for genetic modifiers in 
this disease led to the detection of a concomitant junctophilin-1 (JPH1) change which modified GDAP1 function 
in one of the families with the p.R120W mutation included in this series22. JPH1 substitutions have been detected 
in two other families, one of them is represented in Fig. 3 where the moderately affected siblings have inherited 
a change in JPH1 from their mother, and the p.R120W GDAP1 mutation from their practically asymptomatic 
father (in press). In any case, important clinical variability can be found in at least 6 other families with the 
p.R120W mutation and no concomitant changes in JPH1 have been detected.
Minor differences could be established between the phenotype in the p.R226del and p.R120W mutations 
but these have to be interpreted in the context of the clinical variability inherent to this disease. In the p.R120W 
Genotype Age
Disease 
course (years) CMTNS IFM Soleus Gastrocnemius DPC AC LC Thigh
p R120W 71 A 0* 2 2 2 4 4 4 NP
p R120W 51 A 1* NP 0 0 0 0 0 NP
p R120W 50 5 2* NP 0 0 0 0 0 NP
p R120W 23 3 3 3 2 3 0 0 1 NP
p R120W 37 A 3 3 0 0 0 0 0 NP
p R120W 49 10 4* 3 2 2 0 0 0 NP
p R120W 56 A 4 NP 0 0 0 0 0 NP
p R120W 52 34 4* 4 4 4 1 2 2 NP
p R120W 40 A 5 2 1 1 0 0 0 NP
p R120W 38 6 7 3 1 2 0 0 1 NP
p R120W 27 21 8 NP 4 4 0 1 0 1
p R120W 68 18 9 4 4 4 2 3 3 1
p R120W 24 12 10 2 1 1 0 0 0 NP
p R120W 20 6 10 4 4 4 2 3 3 3
p R120W 32 23 11* 4 3 4 0 1 1 NP
p R120W 58 43 11* 4 4 3 3 1 2 2
p.R120W 31 18 13 4 3 3 2 2 3 NP
p R120W 55 50 17 4 4 4 4 4 4 3
p R120W 73 48 26 4 4 4 3 4 3 3
p.R226del 55 50 8 3 4 3 3 2 2 2
p.R226del 45 A 2 NP 0 0 0 0 0 0
p.Q163X/p.L344R 49 37 12 4 4 4 4 3 3 3
Table 4. Muscle magnetic resonance imaging of the lower limbs. CMTNS: Charcot-Marie-Tooth neuropathy 
score, IFM: Intrinsic foot muscles, DPC: Deep posterior compartment of the calf, AC: Anterior compartment of 
the calf, LC: Lateral compartment of the calf, A: Asymptomatic, *CMTES score values, NP: Not performed.
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mutation ankle flexion weakness could be detected as soon as ankle extension weakness, and fatty substitution 
predominated in the posterior compartment of the calf, while in the p.R226del mutation the MRI findings were 
similar in the symptomatic patient, but in the clinical examination ankle extension weakness predominated. In 
any case the description of more patients will be necessary to confirm these findings.
Autosomal dominant GDAP1 mutations have been described as having an incomplete penetrance, but in this 
series all asymptomatic patients had detectable abnormalities in clinical examination or ancillary testing except 
one. Of the 16 asymptomatic patients 9 had abnormalities in the examination, 11/12 in the electrophysiological 
studies and 3/6 in the MRI. The only patient that had normal examination and ancillary tests did not undergo 
needle electromyography or feet MRI, which are the most sensitive tests in this series. This is in keeping with the 
findings in the Italian p.Arg120Gly mutation where the phenotypic variability mimicked a reduced penetrance, 
but electrophysiological studies were unequivocally abnormal in affected patients23.
These findings enhance the complexity of the clinical phenotype and of predicting the clinical course in GDAP1 
mutations. This last can be especially challenging, but is necessary for the development of future clinical trials. In 
this regard there are several considerations that are important in this CMT subtype. In AR patients the severity of 
the phenotype determined that the scales employed could not adequately assess disease progression except in the 
first or second decade, as afterwards there was a clear ceiling effect in both the CMTNS and FDS scales. In these 
patients ancillary testing could contribute scarcely as MRI of the lower limbs was affected to a great degree and the 
rate of change in these patients would be difficult to interpret. In AD patients, apart from the intra-familiar varia-
bility, the analysis of the available longitudinal information shows that the change rate of CMTNS per year in one 
same patient can be quite variable (data not shown). The responsiveness to change probably could be improved if 
the CMTNS version 2, or the Rasch-wheighted CMTNS version 2 scores had been used, but this was impossible as 
radial nerve conduction studies were available for only a minority of the patients24. In any case, taking into account 
the rarity of this CMT subtype, and the intra-familiar variability, more objective measures of disease progression 
will be necessary, like the MRI biomarkers that have already been developed for CMT1A25.
This is the largest clinical series of CMT patients with GDAP1 mutations and it contributes to expand the 
knowledge of the genetic distribution and genotype-phenotype correlation of this disease.
Methods
Subjects. This cross-sectional retrospective observational study included all CMT patients with causative 
GDAP1 mutations evaluated at 14 centers throughout Spain during the 2000–2016 timeframe. 74 Patients were 
selected from a nationwide register of hereditary neuropathies including 1405 patients, 307 of them defined as 
CMT2. This registry was developed in 2012 being part of the Spanish Registry of Neuromuscular Diseases project 
(NMD-ES). After a call for patients in the Neuromuscular Work Group of the Spanish Neurology Society (SEN), 25 
other patients were identified. All patients included have signed an informed consent form specific for the NMD-ES 
registries which was approved by the Ethics Committee of the Hospital de la Santa Creu i Sant Pau. Genetic, demo-
graphic, clinical, electrophysiological, and pathologic information was evaluated. Only genetically confirmed 
patients were included. All experiments were performed in accordance with relevant guidelines and regulations.
Mutational analysis. Mutation analysis of the GDAP1 gene (NM_018972.2) was performed mostly in the 
same center as previously described using an Applied Biosystems 3730xl DNA analyzer (Foster City, CA, USA)1. 
To investigate the novelty of the identified variants, the following databases were consulted: dbSNP (http://www.
ncbi.nlm.nih.gov/SNP), ESP6500 (http://evs.gs.washington.edu/EVS/), ExAC (http://exac.broadinstitute.org/), 
and CSVS (http://csvs.babelomics.org/). In silico analysis was performed to predict the pathogenicity of the novel 
variants, using SIFT (http://sift.bii.a-star.edu.sg/) and PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/) algo-
rithms for missense changes and NNSPLICE v0.9 (http://www.fruitfly.org/seq_tools/splice.html) for splicing 
alterations. Whenever possible, segregation analysis was performed.
Clinical assessments. A standardized history and symptom questionnaire was employed to collect the basal 
information. Clinical examinations included strength using the standard Medical Research Council (MRC) scale, 
pinprick and vibratory sensory loss, reflexes, as well as a general and neurologic examination. Severity of the 
neuropathy was evaluated with the CMT neuropathy score version 1 (CMTNSv1) as a significant proportion of 
these patients had not undergone the neurophysiologic radial nerve testing which is mandatory for the CMTNS 
version 226, 27. The CMT examination score (CMTES) was used for patients without nerve conduction studies. 
The functional disability scale (FDS), which grades the functional impairment from 0–8, was used to measure the 
disability status28. Respiratory dysfunction was defined by standard spirometry values in each center.
Nerve conduction studies. Motor and sensory nerve conduction velocities (NCVs) were performed using 
standard techniques. Temperature was controlled during the procedure and kept at more than 32 °C. Compound 
muscle action potential amplitudes (CMAP), sensory nerve action potential amplitudes (SNAP), conduction 
velocities and distal latencies were recorded.
Muscle magnetic resonance imaging (MRI). MRI was performed on the feet and distal legs. The protocol 
employed was the same as described previously, and fatty substitution was graded from 0 to 4 as follows: 0, no fat 
signal in muscle; 1, some fatty streaks; 2, fat occupying a minor part of muscle; 3, similar amount of fat and muscle 
tissue; 4, fat occupying the greater part of muscle16, 29. The muscles in the calf were grouped according to 4 ana-
tomical compartments: anterior compartment (tibialis anterior, extensor hallucis longus, and extensor digitorum 
longus), lateral compartment (peronei longus and brevis), superficial posterior compartment (soleus and gastroc-
nemius), and deep posterior compartment (tibialis posterior, flexor digitorum longus, and flexor hallucis longus).
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Nerve pathology. Sural nerve biopsy was performed before the genetic diagnosis was confirmed, or for 
investigational reasons after specific informed consent. Sections were evaluated under a light microscope, and 
morphometric data was analyzed when available18.
Statistical studies. Patient characteristics, data from clinical examination, electrophysiological, examina-
tion and physical disability were analyzed using descriptive statistics with the program R (version 3.3.3), the 
ordinal package (version 2015.6–28) and brglm (0.5–9). A logistic regression model was developed to determine 
the co-variables that could predict a higher CMTNS score.
Data Availability. The datasets generated during and/or analyzed during the current study are available from 
the corresponding author on reasonable request.
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